Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1Phase 1 1

Status

Active not recruiting 4Recruiting 1

Sponsor Class

OTHER 9INDUSTRY 5NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 3Gynecologic 2

Conditions

Ovarian Neoplasms 2Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Metastatic Castration-sensitive Prostate Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 135Carboplatin 111Paclitaxel 68Cisplatin 65Gemcitabine 62Pemetrexed 59Bevacizumab 50Docetaxel 47Fluorouracil 42Oxaliplatin 40Leucovorin 35Dexamethasone 35130-nm albumin-bound paclitaxel 34durvalumab 32atezolizumab 32Cetuximab 32Nivolumab 31Capecitabine 28Rituximab 27Cyclophosphamide 27Prednisone 26Fulvestrant 25enzalutamide 23Lenalidomide 23Letrozole 22venetoclax 21Irinotecan 21Doxorubicin 19ribociclib 16pomalidomide 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × niraparib × 30 days × Clear all
NCT03748641 2026-06-05

MAGNITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
765 enrolled 16 charts 1 FDA
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT04497844 2026-06-05

AMPLITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
696 enrolled 15 charts 1 FDA
Genitourinary

Metastatic Castration-sensitive Prostate Cancer

NCT04577833 2026-06-05

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

Janssen Research & Development, LLC

Phase 1 Active not recruiting
136 enrolled
Genitourinary

Prostatic Neoplasms

NCT06433219 2026-06-03

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

EMD Serono

Phase 2 Active not recruiting
63 enrolled
Gynecologic

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

NCT06915025 2026-06-02

OVATION-3

Imunon

Phase 3 Recruiting
500 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡